Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지
DOI QR코드

DOI QR Code

The effect of melatonin on prevention of bisphosphonate-related osteonecrosis of the jaw: an animal study in rats

  • Yadegari, Afshin (Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Isfahan (Khorasgan) Branch, Islamic Azad University) ;
  • Aminzadeh, Atousa (Department of Oral Pathology, Faculty of Dentistry, Isfahan (Khorasgan) Branch, Islamic Azad University) ;
  • Seyyedkhamesi, Sam (Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Isfahan (Khorasgan) Branch, Islamic Azad University) ;
  • Aminian, Maedeh (Department of Oral and Maxillofacial Radiology, School of Dentistry, Isfahan University of Medical Science)
  • Received : 2019.07.06
  • Accepted : 2019.08.17
  • Published : 2020.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: Melatonin induces human stem cells, converts pre-osteoblasts to mature osteoblasts, and reduces the duration of this transition. However, melatonin itself prevents activation of osteoclasts. Here, we evaluate the role of melatonin in prevention of bisphosphonate-related osteonecrosis of the jaw. Materials and Methods: In this experimental-interventional study, 30 rats were evaluated in 3 groups. The first and second groups received saline and zoledronic acid, respectively, for 4 weeks and the third group received 4 weeks of zoledronic acid and 3 weeks of melatonin simultaneously. First-right-maxillary-molar extraction was performed for all animals, which were sacrificed after 4 weeks of recovery. The extraction sockets were examined histologically for the presence of osteonecrosis, number of osteoclasts and fibroblasts, severity of inflammation, and vascularization. Data were analyzed by chi-square, one-way ANOVA, Tukey, Kruskal-Wallis and Fisher's exact statistical tests (α=0.05). Results: Osteonecrosis was observed in 20%, 90%, and 70% of the first, second and third groups, respectively (P=0.008). The lowest number of osteoclasts and fibroblasts was seen in the third group. Conclusion: Melatonin may effectively prevent some undesirable side effects of bisphosphonates. However, further studies are required to confirm the results of this study.

Keywords

References

  1. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al.; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:1938-56. https://doi.org/10.1016/j.joms.2014.04.031
  2. Ikebe T. Pathophysiology of BRONJ: drug-related osteoclastic disease of the jaw. Oral Sci Int 2013;10:1-8. https://doi.org/10.1016/S1348-8643(12)00045-6
  3. Kaibuchi N, Iwata T, Yamato M, Okano T, Ando T. Multipotent mesenchymal stromal cell sheet therapy for bisphosphonaterelated osteonecrosis of the jaw in a rat model. Acta Biomater 2016;42:400-10. https://doi.org/10.1016/j.actbio.2016.06.022
  4. Colella G, Campisi G, Fusco V. American Association of Oral and Maxillofacial Surgeons position paper: bisphosphonate-related osteonecrosis of the jaws-2009 update: the need to refine the BRONJ definition. J Oral Maxillofac Surg 2009;67:2698-9. https://doi.org/10.1016/j.joms.2009.07.097
  5. Kos M, Kuebler JF, Luczak K, Engelke W. Bisphosphonaterelated osteonecrosis of the jaws: a review of 34 cases and evaluation of risk. J Craniomaxillofac Surg 2010;38:255-9. https://doi.org/10.1016/j.jcms.2009.06.005
  6. Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Sturzenbaum S, et al. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg 2012;40:303-9. https://doi.org/10.1016/j.jcms.2011.05.003
  7. Pichardo SE, van Merkesteyn JP. Bisphosphonate related osteonecrosis of the jaws: spontaneous or dental origin? Oral Surg Oral Med Oral Pathol Oral Radiol 2013;116:287-92. https://doi.org/10.1016/j.oooo.2013.05.005
  8. Vaszilko M, Kovacs E, Restar L, Balla B, Cseplo K, Kosa J, et al. Potential significance of antiestrogen therapy in the development of bisphosphonate related osteonecrosis of the jaw. J Craniomaxillofac Surg 2014;42:1932-6. https://doi.org/10.1016/j.jcms.2014.08.002
  9. Voss PJ, Joshi Oshero J, Kovalova-Muller A, Veigel Merino EA, Sauerbier S, Al-Jamali J, et al. Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients. J Craniomaxillofac Surg 2012;40:719-25. https://doi.org/10.1016/j.jcms.2012.01.005
  10. Udell J. Osteonecrosis [Internet]. Atlanta (GA): American College of Rheumatology [cited 2019 Feb 9]. Available from: https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Osteonecrosis.
  11. Udell J. Osteonecrosis of the jaw [Internet]. Atlanta (GA): American College of Rheumatology [cited 2019 Feb 9]. Available from: https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Osteonecrosis.
  12. Keskinruzgar A, Bozdag Z, Aras MH, Demir T, Yolcu U, Cetiner S. Histopathological effects of teriparatide in medication-related osteonecrosis of the jaw: an animal study. J Oral Maxillofac Surg 2016;74:68-78. https://doi.org/10.1016/j.joms.2015.07.005
  13. Dayisoylu EH, Senel FC, Ungor C, Tosun E, Cankaya M, Ersoz S, et al. The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study. Int J Oral Maxillofac Surg 2013;42:1475-80. https://doi.org/10.1016/j.ijom.2013.05.001
  14. Zandi M, Dehghan A, Mohammadi-Mofrad A, Amini P, Vahdatinia F. Short-term perioperative teriparatide therapy for the prevention of medication-related osteonecrosis of the jaw: a randomized, controlled preclinical study in rats. J Craniomaxillofac Surg 2017;45:275-80. https://doi.org/10.1016/j.jcms.2016.12.010
  15. Del Fabbro M, Gallesio G, Mozzati M. Autologous platelet concentrates for bisphosphonate-related osteonecrosis of the jaw treatment and prevention. A systematic review of the literature. Eur J Cancer 2015;51:62-74. https://doi.org/10.1016/j.ejca.2014.10.015
  16. Ogata K, Katagiri W, Osugi M, Kawai T, Sugimura Y, Hibi H, et al. Evaluation of the therapeutic effects of conditioned media from mesenchymal stem cells in a rat bisphosphonate-related osteonecrosis of the jaw-like model. Bone 2015;74:95-105. https://doi.org/10.1016/j.bone.2015.01.011
  17. Lopez-Jornet P, Camacho-Alonso F, Martinez-Canovas A, Molina-Minano F, Gomez-Garcia F, Vicente-Ortega V. Perioperative antibiotic regimen in rats treated with pamidronate plus dexamethasone and subjected to dental extraction: a study of the changes in the jaws. J Oral Maxillofac Surg 2011;69:2488-93. https://doi.org/10.1016/j.joms.2011.02.059
  18. Yanik S, Aras MH, Erkilic S, Bozdag Z, Demir T, Cetiner S. Histopathological features of bisphosphonates related osteonecrosis of the jaw in rats with and without vitamin d supplementation. Arch Oral Biol 2016;65:59-65. https://doi.org/10.1016/j.archoralbio.2015.10.010
  19. Koneski F, Popovic-Monevska D, Gjorgoski I, Krajoska J, Popovska M, Muratovska I, et al. In vivo effects of geranylgeraniol on the development of bisphosphonate-related osteonecrosis of the jaws. J Craniomaxillofac Surg 2018;46:230-6. https://doi.org/10.1016/j.jcms.2017.11.007
  20. Najeeb S, Khurshid Z, Zohaib S, Zafar MS. Therapeutic potential of melatonin in oral medicine and periodontology. Kaohsiung J Med Sci 2016;32:391-6. https://doi.org/10.1016/j.kjms.2016.06.005
  21. Carpentieri AR, Peralta Lopez ME, Aguilar J, Sola VM. Melatonin and periodontal tissues: molecular and clinical perspectives. Pharmacol Res 2017;125(Pt B):224-31. https://doi.org/10.1016/j.phrs.2017.09.003
  22. Gomez-Florit M, Ramis JM, Monjo M. Anti-fibrotic and antiinflammatory properties of melatonin on human gingival fibroblasts in vitro. Biochem Pharmacol 2013;86:1784-90. https://doi.org/10.1016/j.bcp.2013.10.009
  23. Ramirez-Fernandez MP, Calvo-Guirado JL, de-Val JE, Delgado-Ruiz RA, Negri B, Pardo-Zamora G, et al. Melatonin promotes angiogenesis during repair of bone defects: a radiological and histomorphometric study in rabbit tibiae. Clin Oral Investig 2013;17:147-58. https://doi.org/10.1007/s00784-012-0684-6
  24. Soybir G, Topuzlu C, Odabas O, Dolay K, Bilir A, Koksoy F. The effects of melatonin on angiogenesis and wound healing. Surg Today 2003;33:896-901. https://doi.org/10.1007/s00595-003-2621-3
  25. Nakamura E, Kozaki K, Tsuda H, Suzuki E, Pimkhaokham A, Yamamoto G, et al. Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma. Cancer Sci 2008;99:1390-400. https://doi.org/10.1111/j.1349-7006.2008.00838.x
  26. Cutando A, Arana C, Gomez-Moreno G, Escames G, Lopez A, Ferrera MJ, et al. Local application of melatonin into alveolar sockets of beagle dogs reduces tooth removal-induced oxidative stress. J Periodontol 2007;78:576-83. https://doi.org/10.1902/jop.2007.060244
  27. Barba-Recreo P, Del Castillo Pardo de Vera JL, Garcia-Arranz M, Yebenes L, Burgueno M. Zoledronic acid - related osteonecrosis of the jaws. Experimental model with dental extractions in rats. J Craniomaxillofac Surg 2014;42:744-50. https://doi.org/10.1016/j.jcms.2013.11.005
  28. Zandi M, Dehghan A, Malekzadeh H, Janbaz P, Ghadermazi K, Amini P. Introducing a protocol to create bisphosphonate-related osteonecrosis of the jaw in rat animal model. J Craniomaxillofac Surg 2016;44:271-8. https://doi.org/10.1016/j.jcms.2015.12.010
  29. Wayama MT, Yoshimura H, Ohba S, Yoshida H, Matsuda S, Kobayashi J, et al. Diminished progression of periapical lesions with zoledronic acid in ovariectomized rats. J Endod 2015;41:2002-7. https://doi.org/10.1016/j.joen.2015.08.029
  30. Jabbour Z, do Nascimento C, El-Hakim M, Henderson JE, de Albuquerque Junior RF. Bacterial profile and bone healing in rats receiving cancer therapeutic doses of bisphosphonates and corticosteroids: a pilot study. Int J Oral Maxillofac Surg 2016;45:1162-9. https://doi.org/10.1016/j.ijom.2015.12.017
  31. Cutando A, Aneiros-Fernandez J, Lopez-Valverde A, Arias-Santiago S, Aneiros-Cachaza J, Reiter RJ. A new perspective in oral health: potential importance and actions of melatonin receptors MT1, MT2, MT3, and RZR/ROR in the oral cavity. Arch Oral Biol 2011;56:944-50. https://doi.org/10.1016/j.archoralbio.2011.03.004
  32. Kara A, Akman S, Ozkanlar S, Tozoglu U, Kalkan Y, Canakci CF, et al. Immune modulatory and antioxidant effects of melatonin in experimental periodontitis in rats. Free Radic Biol Med 2013;55:21-6. https://doi.org/10.1016/j.freeradbiomed.2012.11.002
  33. Reiter RJ, Rosales-Corral SA, Liu XY, Acuna-Castroviejo D, Escames G, Tan DX. Melatonin in the oral cavity: physiological and pathological implications. J Periodontal Res 2015;50:9-17. https://doi.org/10.1111/jre.12176
  34. Arabaci T, Kermen E, Ozkanlar S, Kose O, Kara A, Kizildag A, et al. Therapeutic effects of melatonin on alveolar bone resorption after experimental periodontitis in rats: a biochemical and immunohistochemical study. J Periodontol 2015;86:874-81. https://doi.org/10.1902/jop.2015.140599
  35. Ruggierro SL. Diagnostic and management of medication-related osteonecrosis of the jaw. In: Fonseca RJ, ed. Oral and maxillofacial surgery. 3rd ed. St. Louis: Elsevier; 2018:507-22.